Biotech products and processes evolve over time. This can cause a misalignment between your issued/pending patent claims, and your...

INTRODUCTION Executives usually ask these quantitative but high-level questions: How much money did we spend on patent work this year?...

As a biotech company, much of your value is in (pre-revenue) and/or protected by (post-revenue) your intellectual property. As you...

Working examples are an important part of a biotech patent application, especially because this is considered an unpredictable art in...

SUMMARY Costs for prosecuting patents at the USPTO are set to increase on 1/19/25 Across-the-board 7.5% increase in fees Some targeted...

Like many technology areas, the vast majority of, if not all, biotech/biopharma inventions build on prior art teachings. Thus, a major...

The USPTO has provided 49 examples* to help understand the application of Section 101 (35 U.S.C. 101), subject matter eligibility, in...

Common misconceptions about patent rights: In my decades of counseling life sciences companies, I have found that many inventors and...

When should we assure we have FTO for our private biotech company? Summary: FTO for a private biotech company is typically a multi-stage...

101 rejections at the USPTO plummeted in computational biology in 2023!      We analyzed office actions since 2008 related to...

INTRODUCTORY COMMENTS RE: BIOTECH/PHARMA EXTENDED PATENT FAMILIES In complex art areas like biotech/biopharma, patent strategy is about...

The $AMRN/Vascepa story... A sad 🥲 but insightful🤔 story about the value of U.S. biopharma patents From ~$23/share to ~$1/share in ~5...

If you are interested in learning more about prior patent term extension filings, the USPTO and FDA provide some helpful links, which are...

March 26, 2023 The U.S. Supreme Court will hear oral arguments tomorrow in Amgen v. Sanofi, an important biotech enablement case. The...